Cited by 384Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchIntracerebral and Subarachnoid Hemorrhage Research

Vascular Pathology in Alzheimer Disease: Correlation of Cerebral Amyloid Angiopathy and Arteriosclerosis/Lipohyalinosis with Cognitive Decline

Thal, Dietmar Rudolf, Ghebremedhin, Estifanos, Orantes, Mario, Wiestler, Otmar D.·2003·Journal of Neuropathology & Experimental Neurology

Abstract

Sporadic, late-onset Alzheimer disease (AD) constitutes the most frequent cause of dementia in the elderly population. AD-related pathology is often accompanied by vascular changes. The predominant vascular lesions in AD are cerebral amyloid angiopathy (CAA) and arteriosclerosis/lipohyalinosis (AS/LH). The present study was carried out to examine the coincidence of these small vessel pathologies during the development of cognitive deficits, amyloid beta-protein (A beta) deposition, and neurofibrillary tangle (NFT) formation in sporadic late-onset AD. We correlated the clinical dementia rating (CDR) score, the sequential extension of AD-related A beta deposition into different parts of the brain, and the extension of NFTs to involve more brain regions with the distribution of CAA and AS/LH in 52 human autopsy brains. The extension of CAA and AS/LH to involve different areas of the brain was associated with a rise of CDR scores and an increase in the extension of A beta deposition and NFT generation. AD cases showed a higher number of regions with CAA and AS/LH compared to nondemented patients with AD-related pathology and controls. Moreover, we demonstrated a hierarchical sequence in which the different regions of the brain exhibited CAA and AS/LH-affected vessels, allowing the distinction of 3 stages in the development of CAA and AS/LH. The first stage of CAA involved leptomeningeal and neocortical vessels. The second stage was characterized by additional A beta deposition in allocortical and midbrain vessels. Finally, in a third stage, CAA was observed in the basal ganglia, the thalamus, and in the lower brainstem. In contrast, AS/LH initially affected the basal ganglia in stage A. In stage B this pathology made inroads into the deep white matter, the leptomeningeal arteries of the cortex, the cerebellum, and into the thalamus. Stage C was characterized by AS/LH in brainstem vessels. Our results demonstrate widespread CAA and AS/LH to be associated with the development of cognitive deficits in AD. A combination of both CAA and AS/LH may, therefore, contribute to neurodegeneration in AD. These data also suggest that small vessel disease due to arteriosclerosis and fibrolipohyalinosis is a potential target for the treatment of AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnen/62.12.1287

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both CAA and CCA variants of VAβ pathology have been described in AD autopsies and their relative preponderance has been linked to various APOE genotypes.

    “Both CAA and CCA variants of VAβ pathology have been described in AD autopsies and their relative preponderance has been linked to various APOE genotypes [40–43].”

    From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [41]

    The CAA section (page unavailable) reports capillary amyloid-β deposits in autopsy cases and describes them as indicative of an APOE ε4-associated type of CAA. The APOE section (page unavailable) finds more extensive CAA in ε4 carriers. Neither passage establishes the relative preponderance of CAA and capillary variants across APOE genotypes. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 51 references couldn’t be matched to a known paper.

Research works printed but not linked: 5

  1. Esiri MM, Hyman BT, Beyreuther K, et al. Ageing and dementia. In: Lantos PL, ed. Greenfields neuropathology, 6th Edition. Lon- don: Arnold, 1997:153-233
  2. Kim KS, Miller DL, Sapienza VJ, et al. Production and character- ization of monoclonal antibodies reactive to synthetic cerebrovas- cular amyloid peptide. Neurosci Res Commun 1988;2:121-30
  3. Kalimo H, Kaste M, Haltia M. Vascular diseases. In: Lantos PL. Greenfield's neuropathology, 6th Edition. London: Arnold, 1997: 315-96
  4. Weller RO, Massey A, Newman TA, et al. Cerebral amyloid an- giopathy: Amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998;153: 725-33
  5. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIR- EN International Workshop. Neurology 1993;43:250-60

Cited by

Sorted by citations

Authors
Thal, D. R., Ghebremedhin, E., Orantes, M., & Wiestler, O. D.
Affiliations
  • University of Bonn (DE)
  • Goethe University Frankfurt (DE)
Corresponding author
Thal, Dietmar Rudolf
Venue
Journal of Neuropathology & Experimental Neurology
Published
2003-12
Volume
62
Issue
12
Pages
1287-1301
ISSN
  • 0022-3069 (ISSN-L)
  • 1554-6578
OpenAlex
W1603244154
Cited by
384
References
51
Citations by year
2026: 11 · 2025: 19 · 2024: 14 · 2023: 14 · 2022: 29 · 2021: 23 · 2020: 26 · 2019: 22 · 2018: 15 · 2017: 10 · 2016: 15 · 2015: 22 · 2014: 23 · 2013: 21 · 2012: 11
FWCI
5.38
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Neuropathology & Experimental Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
Deutsche Forschungsgemeinschaft (TH624 4–1)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Intracerebral and Subarachnoid Hemorrhage Research
Keywords
Alzheimer's disease, cerebral amyloid angiopathy, arteriosclerosis, lipohyalinosis, cerebral small vessel disease, cognitive decline, amyloid-beta deposition, neurofibrillary tangles, disease staging, vascular pathology, dementia, neurodegeneration
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Analysis of Variance, Intracranial Arteriosclerosis, Cognition Disorders, Female, Humans, Male, Middle Aged, Cerebral Amyloid Angiopathy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review